Research programme: small molecule inhibitors - Molecure/University of Michigen
Latest Information Update: 29 Apr 2024
Price :
$50 *
At a glance
- Originator University of Michigan
- Developer Molecure; University of Michigan
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis; Idiopathic pulmonary fibrosis
Most Recent Events
- 29 Apr 2024 Molecure plans a preclinical trial in Fibrosis in 2025 (Molecure pipeline, April 2024)
- 11 Mar 2022 OncoArendi Therapeutics and University of Michigan enter into a license option agreement for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis
- 11 Mar 2022 Early research in Fibrosis in Poland (unspecified route)